The GOOD, the BAD and the ... OLD: RNA VACCINE fights CANCER with RADIOTHERAPY
Therapeutic RNA lipoplex (LPX) - cancer vaccines have shown great promise in various pre-clinical (Kreiter S. et al Nature 2015, Kranz L. et al., Nature 2016), and clinical trials (Sahin U. et al. Nature 2017) driving anti-tumour immune responses. RNA-LPX vaccination resulted in induction of potent and long-lived antigen specific T cells, promoting tumour control, in same case potent rejection of well-established tumours, allowing modulation of the tumour environment.
Selected preclinical study will be presented to describe the benefits achieved using RNA vaccines in combination therapies. In particular, the use of standard clinical care, such as local radiotherapy, with systemic RNA-LPX vaccination encoding for tumor antigens has been recently assessed generating attractive new applications of RNA –LPX vaccines in clinic for cancer patients.
Johannes Gutenberg-Universität Mainz gemeinnützige GmbH
Head Vaccines & Cellular Immunotherapy
Domain 3 - U932 - Immunity and Cancer
Domain 1 - UMR 3347 / U1021 - Normal and pathological signaling